AUTHORS
Antonina Kurtova, Nicholas Stong, PhD2, Alberto Risueño, PhD3, Tracy T. Chow, PhD4, Luciano J. Costa, MD, PhD5, Rakesh Popat, MD6, Fredrik Schjesvold, MD,PhD7, David S Siegel, MD, PhD8, Clifton C. Mo, MD9, Nizar Bahlis, MD10, Albert Oriol Sr, MD11, Saad Z. Usmani, MD12, Syed Abbas Ali, MBBS13, Michael Chu, MD, FRCPC14, Karthik Ramasamy, MD PhD15, Joaquin Martinez-Lopez Sr, MD, PhD16, Enrique Ocio Sr, MD, PhD17, Donna Reece, M.D.18, Emma Searle, MBChB, PhD19, Rafael Sarmiento, PharmD20, August Dietrich, MD21, Soraya Carrancio, PhD22, Paul G. Richardson, MD23
AFFILIATIONS
1 Bristol Myers Squibb, Princeton, New Jersey, United States
2 Bristol Myers Squibb, Princeton, New Jersey, United States
3 Bristol Myers Squibb, Princeton, New Jersey, United States
4 Bristol Myers Squibb, Princeton, New Jersey, United States
5 The University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University College London Hospitals NHS Foundation Trust, London, United Kingdom
7 Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
8 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
11 Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
14 University of Alberta, Edmonton, Alberta, Canada
15 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
16 Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain
17 Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
18 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
19 The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
20 Bristol Myers Squibb Center for Innovation and Translational Research Europe (CITRE), Seville, Spain
21 Bristol Myers Squibb, Princeton, New Jersey, United States
22 Bristol Myers Squibb, Princeton, New Jersey, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: Mezigdomide (MEZI), a novel, potent oral CELMoD, induces rapid degradation of Ikaros and Aiolos, resulting in direct tumoricidal and immunomodulatory effects in myeloma cells and reactivation of anti-tumor immunity. MEZI + dexamethasone (MEZId) in combination with novel agents, such as tazemetostat (TAZ), the bromodomain inhibitor (BETi) BMS-986158, and trametinib (TRAM) showed promising efficacy and safety in the phase 1/2 CA057-003 trial (NCT05372354) in pts with RRMM, including those post- T-cell redirecting therapies (TCRT). Whether prior exposure to TCRTs and response to the most recent TCRT influence subsequent immune reconstitution or the ability of MEZI-based therapy to reactivate immune function in late line RRMM patients remains unclear. To address this, we characterized baseline and on-treatment peripheral blood immunophenotypes in patients enrolled in CA057-003 according to prior TCRT exposure and response to the most recent last-line TCRT.
Methods: Pts with RRMM (n = 76) with documented progressive disease during or after the last regimen had received MEZId-based combinations with TAZ (n = 16), BETi (n = 20) and TRAM (n = 40). The MEZI dose received was 0.3-1.0 mg daily for 21/28 days. Last line regimen included TCRT for 40 pts (n=26 responders to TCRT, n=13 non-responders to TCRT, n=1 no data), or various non-TCRT regimens for the other 36 pts. Peripheral blood samples were collected at Cycle 1 Day 1 pre-treatment, and at various timepoints during C1 on treatment for evaluation of multiple immune markers. Immune phenotyping from peripheral blood samples was performed using multicolor flow cytometry
Results: At baseline (C1D1), absolute counts and relative frequencies of monocytes, B, NK, NKT, and T cells (including CD4+ and CD8+ subsets) were similar across noTCRT, TCRT responder, and TCRT non-responder groups. Baseline proliferating (Ki-67+) CD4+ T cells were significantly higher in TCRT non-responders than TCRT responders, with a similar trend for HLA-DR+ CD4+ T cells. ICOS+ and HLA-DR+ NK/NKT cells, Treg frequency, CD4:CD8 ratio , PD1+ CD4+ and CD8+ T cells, and memory subset distribution did not differ significantly across groups. On treatment, MEZId combinations induced increases in Ki-67+ and HLA-DR+ CD4+ and CD8+ T cells from C1D1 across all 3 subgroups, peaking around C1D15, indicating T-cell proliferation and activation regardless of prior last line TCRT exposure or response. A parallel shift from naive/central memory toward effector memory/TEMRA compartments was observed in CD4+ and CD8+ T cells across all subgroups during Cycle 1, most pronounced for CD8+ effector memory cells. PD1+ CD4+ and CD8+ T-cell frequency decreased modestly from C1D1 to C1D15 in the noTCRT subgroup.
Conclusions: Prior TCRT exposure and response status had limited impact on baseline immune composition. Across all subgroups, MEZI triplet combinations induced early T-cell proliferation, activation, and a shift toward effector memory phenotypes, supporting the capacity of MEZI to reactivate anti-tumor immunity irrespective of prior TCRT exposure or best response to TCRT. These immune correlative findings support continued clinical development of MEZI combinations in RRMM pts previously treated with TCRT.
DISCLOSURES
Antonina Kurtova: Bristol-Myers Squibb - Current equity holder in publicly-traded company; Bristol-Myers Squibb - Current Employment